Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance.
Blog Post
When Idah Mulalah joined AVAC’s Clinical Trial Design Academy (CTDA) in 2024, she thought it would be like joining any other group where we meet, discuss, learn and move on. In this guest blog post, she reflects on how much the experience has transformed her understanding of clinical trials, and how she sees her role as an HIV prevention research advocate.
Blog Post
The US midterm elections this week brought significant changes to Congress, creating both new opportunities and uncertainties for the future of science, global health and HIV. This is a moment that is both “celebratory and scary,” with much to unpack about what a new Congress will mean for US policies and investments. With potentially more than 100 new members taking office in January, the need for education, engagement and advocacy will be critical to securing supportive policies and sustainable funding for US-led global health programs and research. This issue examines what the election results mean for science and global health, the US FDA regulatory approval of generic lenacapavir for HIV PrEP (LEN), and Mark Dybul’s vision for the Global Fund amid shrinking resources and shifting priorities.
Blog Post
For nearly two years, the US Administration has ignored Congress and denied women and couples of life-saving sexual and reproductive health commodities. So this week’s breaking news that the US Department of State is shifting millions of dollars appropriated by Congress for contraception to “stem some of the bleeding they’ve caused by starting a reckless war and creating a global energy crisis” is perhaps not surprising. But it is appalling, nonetheless. With the US midterm elections happening next week, all members of Congress, irrespective of party or ideology, should be speaking up and taking back their power of the purse.
showing 1-10 of 1279
When Idah Mulalah joined AVAC’s Clinical Trial Design Academy (CTDA) in 2024, she thought it would be like joining any other group where we meet, discuss, learn and move on. In this guest blog post, she reflects on how much the experience has transformed her understanding of clinical trials, and how she sees her role as an HIV prevention research advocate.
Topic:
The US midterm elections this week brought significant changes to Congress, creating both new opportunities and uncertainties for the future of science, global health and HIV. This is a moment that is both “celebratory and scary,” with much to unpack about what a new Congress will mean for US policies and investments. With potentially more than 100 new members taking office in January, the need for education, engagement and advocacy will be critical to securing supportive policies and sustainable funding for US-led global health programs and research. This issue examines what the election results mean for science and global health, the US FDA regulatory approval of generic lenacapavir for HIV PrEP (LEN), and Mark Dybul’s vision for the Global Fund amid shrinking resources and shifting priorities.
For nearly two years, the US Administration has ignored Congress and denied women and couples of life-saving sexual and reproductive health commodities. So this week’s breaking news that the US Department of State is shifting millions of dollars appropriated by Congress for contraception to “stem some of the bleeding they’ve caused by starting a reckless war and creating a global energy crisis” is perhaps not surprising. But it is appalling, nonetheless. With the US midterm elections happening next week, all members of Congress, irrespective of party or ideology, should be speaking up and taking back their power of the purse.
AVAC applauds the appointment of Mark Dybul as Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. His return to the Global Fund comes at a pivotal moment for global health, as funding pressures, political threats and persistent inequities threaten hard-won progress against the three diseases.
International pressure halted a controversial hepatitis B vaccine trial in Guinea-Bissau; HIV advocates rallied to protect US research funding as the midterm elections approach; and AVAC and Access Bridge call for accelerated access to LEN for PrEP. Meanwhile, the Global Fund prepares to select a new leader at its board meeting next week and vote on a proposed $2-3 billion malaria funding mechanism that could reshape the role of private philanthropy and country ownership in global health financing.
AVAC and Access Bridge today issued a global call to action and new publication urging governments, donors, manufacturers, implementers, and advocates to work toward a bold but achievable goal: reaching at least three million people with injectable lenacapavir (LEN) for HIV prevention by the end of 2027. This new, more ambitious target will drive affordability, build a sustainable PrEP market, and accelerate impact.
Prevention Option:
Challenges and scientific progress took center stage at the World Health Summit in Berlin, the UN adopted a new pandemic preparedness declaration, concerns continue over the proposed US-funded hepatitis B vaccine trial in Guinea-Bissau, and proposed changes to NIH’s scientific peer-review process raise new questions about transparency and political influence over research funding.
The US National Institutes of Health (NIH) said its HIV clinical trial networks should “temporarily hold off on launching new studies that had not yet enrolled participants and that would not be complete by November 30, 2027, when their current funding is set to expire.” This potentially devastating development comes as new questions emerge about how billions in US foreign assistance funding were spent, and details on the impacts of an end of US health assistance to Zimbabwe emerge. Also, a new candidate for WHO leadership and growing civil society calls to protect UNAIDS.
Advocacy has always been the heartbeat of progress in the fight against HIV/AIDS. Now, more than ever, it is especially needed to ensure that innovation translates into real choices, equitable access and meaningful impact. In this issue, we highlight the power of coalition advocacy – from advocates working in partnership to shape research agendas and oppose policies that threaten progress, to ensuring communities have a voice in AI development and use, to the lessons learned from sustained, coalition-based advocacy that will shape what comes next.
The power and leadership of advocates were on full display at AIDS 2026. Following global funding cuts and concerns about de-prioritization of communities and civil society, advocates brought evidence of their impact and the value of continued investment in communities to Rio. On topics ranging from HIV prevention access to the future of artificial intelligence in HIV programs, advocates were driving conference discussions to ensure the community agenda was seen, heard and acted upon.
showing 1-10 of 1279
Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.
A comprehensive round-up of HIV prevention media coverage and scientific publications.
Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.
PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.
Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.
A collection of official statements from AVAC.
Media clippings featuring AVAC, its staff and close partners in the news media.